[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629965":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":32,"collaborators":7,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":7,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":7,"maxAge":7,"enrollmentInfo":42,"targetDuration":45,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"name":10,"affiliation":11,"role":12},"Xiao Qiang Ding","Zhongshan Hospital Affiliated with Fudan University","PRINCIPAL_INVESTIGATOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Zhongshan Hospital Affilicated with Fudan University","RECRUITING","Shanghai","China","CN",{"type":27,"coordinates":28},"Point",[29,30],121.45806,31.22222,{"lat":30,"lon":29},{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100629965","a-prospecitve-multicenter-observational-registry-study-100629965",false,"NCT07481526","A Prospecitve Multicenter, Observational Registry Study","A Multicenter Real-World Registry of Characteristics, Treatment Strategies, and Clinical Outcomes in Chinese Adults With Chronic Kidney Disease","Inclusion Criteria:\n\n* Male or female patients aged ≥18 years.\n* Willing and able to provide written informed consent to participate in the study.\n* Confirmed CKD diagnosis at enrolment, defined by at least one of the following:\n\n  * eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m² for ≥3 months, OR\n  * Evidence of kidney damage (e.g., UACR ≥30 mg\u002Fg or UPCR ≥150 mg\u002Fg, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months\n\nExclusion Criteria:\n\n* Having a life-threatening comorbidity with life expectancy \\\u003C 2 years.\n* Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months.\n* Pregnant or breastfeeding women.\n* Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment.\n* Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.","ALL",{"count":43,"type":44},3000,"ESTIMATED","96 Weeks","OBSERVATIONAL","This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.",[49],"Chronic Kidney Disease","2026-07-01",{"date":52,"type":53},"2026-07-02","ACTUAL",{"date":55,"type":53},"2026-02-27",{"date":57,"type":44},"2028-12-30",{"name":5,"class":6},1]